Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
1/2018 not set
Hide and Seq
Hide and Seq Overview
Hide and Seq combines predictive and prognostic biomarkers to promote effective treatment for several types of cancer. The company is developing an in vitro diagnostic genomic signature that identifies which patients should be offered an alternative chemotherapy in first and second lines of treatment.
Hide and Seq is developing a predictive assay for first-line therapy aimed at identifying chemotherapy resistance to paclitaxel (Taxol) in patients with metastatic ovarian cancer. A predictive genetic assay will offer physicians a personally tailored mode of treatment intended to increase treatment efficacy and survival.
Hide and Seq Climate Tech relevance
undefined
Companies you might be interested in
Driven by Finder AI
Latest News
No Data, yet.
Sorry, no content found under this section.
May 23, 2016
www.globes.co.il
Personalized cancer drug co in AbbVie collaboration